Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study

CNS Neuroscience and Therapeutics

Volumn 18, Issue 4, 2012, Pages 302-312

  Koliaki, Chrysi C ^a   Messini, Chaido ^a   Tsolaki, Magda ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Alzheimer's disease; Aniracetam; Cholinesterase inhibitors; Combined treatment; Dementia, Monotherapy; Neuropsychological parameters; Nootropics

Indexed keywords

ANIRACETAM; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ANXIETY; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EMOTIONALITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NEUROPSYCHOLOGICAL TEST; SIDE EFFECT; VOMITING;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PROSPECTIVE STUDIES; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 84859503567     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00244.x     Document Type: Article

References (33)

1. Alzheimer's Association.2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009;5:234-270.
2. Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective. Am J Manag Care 2001;7:809-818.
3. Hurt CS, Banerjee S, Tunnard C, et al. Insight, cognition and quality of life in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2009;81:331-336.
4. Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, del Valle M. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry 2009;24:15-24.
5. Tsuno N, Homma A. What is the association between depression and Alzheimer's disease? Expert Rev Neurother 2009;9:1667-1676.
6. Gillioz AS, Villars H, Voisin T, et al.; for the REAL.FR Group. Spared and impaired abilities in community-dwelling patients entering the severe stage of Alzheimer's disease. Dement Geriatr Cogn Disord 2009;28:427-432.
7. Vellone E, Piras G, Talucci C, Cohen MZ. Quality of life for caregivers of people with Alzheimer's disease. J Adv Nurs 2008;61:222-231.
8. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 2010;7:358-367.
9. Senin U, Abate G, Fieschi C, et al. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): Results of a placebo controlled multicentre clinical study. Eur Neuropsychopharmacol 1991;1:511-517.
10. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593.
11. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:17-28.
12. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y. Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002;24:862-886.
13. Lee CR, Benfield P. Aniracetam An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging 1994;4:257-273.
14. Nakamura K. Aniracetam: Its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev 2002;8:70-89.
15. Endo H, Tajima T, Yamada H, et al. Pharmacokinetic study of aniracetam in elderly patients with cerebrovascular disease. Behav Brain Res 1997;83:243-244.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Folstein MF, Folstein SE, McHugh PR: 'Mini- Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Fountoulakis K, Tsolaki M, Chantzi H, Kazis A. Mini Mental State Examination. A validation study in elderly demented patients in Greece. Enkephalos (Greece) 1994;31:93-102.
19. Hutton TJ: Alzheimer's disease. In: Rakel RE, editor. Conn's current therapy. Philadelphia: WB Saunders, 1990; 780 p.
20. Fountoulakis KN, Tsolaki M, Iacovides A, Yesarage J, O'Hara R, Kazis A, Ierodiaconou C. The validation of the short form of the Geriatric Depression Scale (GDS) in Greece. Aging (Milano) 1999;11:367-372.
21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
22. López-Pousa S, Turon-Estrada A, Garre-Olmo J, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005;19:189-195.
23. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:1-160.
24. Bordier P, Garrigue S, Lanusse S, Margaine J, Robert F, Gencel L, Lafitte A. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. CNS Drugs 2006;20:411-417.
25. Tsolaki M, Pantazi T, Kazis A. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: A retrospective, longitudinal study. J Int Med Res 2001;29:28-36.
26. Canonico V, Forgione L, Paoletti C, et al. Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration. Riv Neurol 1991;61:92-96.
27. Nicoletti F, Casabona G, Genazzani AA, Copani A, Aleppo G, Canonico PL, Scapagnini U. Excitatory amino acids and neuronal plasticity: Modulation of AMPA receptors as a novel substrate for the action of nootropic drugs. Funct Neurol 1992;7:413-422.
28. Nakamura K, Shirane M. Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam. Eur J Pharmacol 1999;380:81-89.
29. Shirane M, Nakamura K. Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S, 3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP. Neuropharmacology 2000;39:866-872.
30. Nakamura K, Shirane M, Koshikawa N. Site-specific activation of dopamine and serotonin transmission by aniracetam in the mesocorticolimbic pathway of rats. Brain Res 2001;897:82-92.
31. Shirane M, Nakamura K. Aniracetam enhances cortical dopamine and serotonin release via cholinergic and glutamatergic mechanisms in SHRSP. Brain Res 2001;916:211-221.
32. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 2004;3:181-194.
33. Kihara M, Nishikawa S, Nakasaka Y, Tanaka H, Takahashi M. Autonomic consequences of brainstem infarction. Auton Neurosci 2001;86:202-207.